Anti-D prophylaxis: Past, present and future

Transfusion Medicine

Volumn 24, Issue 1, 2014, Pages 1-7

  de Haas, M ^a   Finning, K ^b   Massey, E ^b   Roberts, D J ^b,c  

^a Division of Diagnostic Services   (Netherlands)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti D; BCSH guidelines; Prophylaxis

Indexed keywords

RHESUS D ANTIBODY; BLOOD GROUP RHESUS SYSTEM; MONOCLONAL ANTIBODY; RHO(D) ANTIGEN;

ALLOIMMUNIZATION; CESAREAN SECTION; CLINICAL TRIAL (TOPIC); DENMARK; ECTOPIC PREGNANCY; ERYTHROCYTE; GENOTYPE; HUMAN; NETHERLANDS; PRACTICE GUIDELINE; PROPHYLAXIS; PUBLIC HEALTH SERVICE; REVIEW; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; TRANSFUSION; UNITED KINGDOM; BLOOD GROUP RHESUS SYSTEM; BLOOD GROUP TYPING; ERYTHROBLASTOSIS, FETAL; EUROPE; FEMALE; MALE; PREGNANCY; PROCEDURES;

ANTIBODIES, MONOCLONAL; BLOOD GROUPING AND CROSSMATCHING; CLINICAL TRIALS AS TOPIC; ERYTHROBLASTOSIS, FETAL; EUROPE; FEMALE; GENOTYPE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; RH-HR BLOOD-GROUP SYSTEM; RHO(D) IMMUNE GLOBULIN;

EID: 84892643549     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/tme.12099     Document Type: Review

References (41)

1. Brinc, D. & Lazarus, A.H. (2009) Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Hematology American Society of Hematology Education Program, 2009, 185-191.
2. Chilcott, J., Lloyd Jones, M., Wight, J., Wray, J., Beverley, C. & Tappenden, P. (2003) A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. Health Technology Assessment, 7, iii-62.
3. Clausen, F.B., Christiansen, M., Steffensen, R. et al. (2012) Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion, 52, 752-758.
4. Daniels, G., van der, Schoot, C.E. & Olsson, M.L. (2011) Report of the fourth International Workshop on molecular blood group genotyping. Vox Sanguinis, 101, 327-332.
5. Engelfriet, C.P., Reesink, H.W., Judd, W.J. et al. (2003) Current status of immunoprophylaxis with anti-D immunoglobin. Vox Sanguinis, 85, 328-337.
6. Faas, B.H., Beuling, E.A., Christiaens, G.C., von, dem Borne, A.E. & van der, Schoot, C.E. (1998) Detection of fetal RHD-specific sequences in maternal plasma. Lancet, 352, 1196.
7. Finning, K.M., Martin, P.G., Soothill, P.W. & Avent, N.D. (2002) Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion, 42, 1079-1085.
8. Finning, K., Martin, P., Summers, J., Massey, E., Poole, G. & Daniels, G. (2008) Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. British Medical Journal, 336, 816-818.
9. Grootkerk-Tax, M.G., Soussan, A.A., de, Haas, M., Maaskant-van Wijk, P.A. & van der, Schoot, C.E. (2006) Evaluation of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma. Transfusion, 46, 2142-2148.
10. Hamilton, E.G. (1967) Prevention of Rh isoimmunisation by injection of anti-D antibody. Obstetrics and Gynecology, 30, 812-815.
11. Huchet, J., Dallemagne, S., Huchet, C., Brossard, Y., Larsen, M. & Parnet-Mathieu, F. (1987) Ante-partum administration of preventive treatment of Rh-D immunisation in rhesus-negative women. Parallel evaluation of transplacental passage of fetal blood cells. Results of a multicentre study carried out in the Paris region. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction, 16, 101-111.
12. Koelewijn, J.M., de, Haas, M., Vrijkotte, T.G., Bonsel, G.J. & van der, Schoot, C.E. (2008) One single dose of 200microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion, 48, 1721-1729.
13. Kumpel, B.M. (2006) On the immunologic basis of Rh immune globulin (anti-D) prophylaxis. Transfusion, 46, 1652-1656.
14. Lee, D., Contreras, M., Robson, S.C., Rodeck, C.H. & Whittle, M.J. (1999) Recommendations for the use of anti-D immunoglobulin for Rh prophylaxis. British Blood Transfusion Society and the Royal College of Obstetricians and Gynaecologists. Transfusion Medicine, 9, 93-97.
15. Legler, T.J., Liu, Z., Mavrou, A., Finning, K., Hromadnikova, I. & Galbiati, S. (2007) Workshop report on the extraction of foetal DNA from maternal plasma. Prenatal Diagnosis, 27, 824-829.
16. Legler, T.J., Müller, S.P., Haverkamp, A., Grill, S. & Hahnb, S. (2009) Prenatal RhD testing: a review of studies published from 2006 to 2008. Transfusion Medicine and Hemotherapy, 36, 189-198.
17. Lenetix Inc (2013) RHD Genotyping [WWW document]. URL www.lenetix.com (Accessed 23/12/13).
18. Lo, Y.M. (2012) Non-invasive prenatal diagnosis by massively parallel sequencing of maternal plasma DNA. Open Biology, 2, 120086.
19. Lo, Y.M., Tein, M.S., Lau, T.K. et al. (1998a) Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. The American Journal of Human Genetics, 62, 768-775.
20. Lo, Y.M., Hjelm, N.M., Fidler, C. et al. (1998b) Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. The New England Journal of Medicine, 339, 1734-1738.
21. MacKenzie, I.Z., Bowell, P., Gregory, H., Pratt, G., Guest, C. & Entwistle, C.C. (1999) Routine antenatal rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study. British Journal of Obstetrics and Gynaecology, 106, 492-497.
22. Mayne, S., Parker, J.H., Harden, T.A., Dodds, S.D. & Beale, J.A. (1997) Rate of Rh D sensitisation before and after implementation of a community based antenatal prophylaxis programme. British Medical Journal, 315, 1588.
23. Moise, K.J. Jr. & Argoti, P.S. (2012) Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstetrics and Gynecology, 120, 1132-1139.
24. NICE (National Institute for Health and Clinical Excellence). (2002) Full Guidance on the Use of Routine Antenatal Anti-D Prophylaxis for Rh D-Negative Women. Technology Appraisal Guidance No. 41 [WWW document]. URL http://guidance.nice.org.uk/TA156 (Accessed 23/12/13).
25. NICE (National Institute for Health and Clinical Excellence). (2008) Routine Antenatal Anti-D Prophylaxis for Women Who are Rhesus D Negative [WWW document]. URL http://www.nice.org.uk/nicemedia/live/12047/41690/41690.pdf (Accessed on 23/12/13).
26. NICE (National Institute for Health and Clinical Excellence). (2012) Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management in Early Pregnancy of Ectopic Pregnancy and Miscarriage. CG154 [WWW document]. URL http://www.nice.org.uk/nicemedia/live/14000/61854/61854.pdf (Accessed on 23/12/13).
27. Parker J, Wray J, Gooch A, Robson S & Qureshi H (2006) Guidelines for the Use of Prophylactic Anti-D Immunoglobulin [WWW document]. URL http://www.bcshguidelines.com/documents/Anti-D_bcsh_07062006.pdf (Accessed 23/12/13).
28. Qureshi, H., Massey, E., Kirwan, D., Davies, T., Robson, S., White, J., Jones, J. & Allard, S. (2014) The use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and the newborn. Transfusion Medicine, 24, 8-20.
29. RCOG (Royal College of Obstetrics and Gynaecologists). (2011) RCOG Green Top Guideline 22, revised March 2011: The Use of Anti-D Immunoglobulin for Rhesus D Prophylaxis [WWW document]. URL http://www.rcog.org.uk/files/rcog-corp/GTG22AntiD.pdf. (Accessed 23/12/13).
30. Reid, M. & Shine, I. (2012) Rh HDN: prevention and treatment. In: The Discovery and Significance of Blood Groups, 6, 39-56. SBB Books, Cambridge, Massachusetts.
31. Robak, T., Windyga, J., Trelinski, J. et al. (2012) Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood, 120, 3670-3676.
32. Scheffer, P.G., de, Haas, M. & van der, Schoot, C.E. (2011a) The controversy about controls for fetal blood group genotyping by cell-free fetal DNA in maternal plasma. Current Opinion in Hematology, 18, 467-473.
33. Scheffer, P.G., van der, Schoot, C.E., Page-Christiaens, G.C. & de, Haas, M. (2011b) Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. British Journal of Obstetrics and Gynaecology, 118, 1340-1348.
34. van der, Schoot, C.E., Soussan, A.A., Koelewijn, J., Bonsel, G., Page-Christiaens, G.C.M.L. & de, Haas, M. (2006) Non-invasive antenatal RHD typing. Transfusion Clinique et Biologique, 13, 53-57.
35. Sequenom Center for Molecular Medicine. (2013) SensiGene Fetal RHD Genotyping [WWW document]. URL www.sequenomcmm.com (Accessed 23/12/13).
36. Stasi, R. (2010) Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Current Opinion in Molecular Therapeutics, 12, 734-740.
37. Tiblad, E., Taune Wikman, A., Ajne, G. et al. (2013) Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program. PLoS One, 8, e70984.
38. Tovey, L.A.D., Townley, A., Stevenson, B.J. & Taverner, J. (1983) The Yorkshire antenatal anti-D trial in primigravidae. Lancet, 2, 244-246.
39. Urbaniak, S.J. & Greiss, M.A. (2000) Rh D haemolytic disease of the fetus and the newborn. Blood Reviews, 14, 44-61.
40. Yver, A., Homerym, M.C., Fuseaum, E., Guemasm, E., Dhainaut, F., Quagliaroli, D., Beliard, R. & Prost, J.F. (2012) Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FCγRIII, in healthy volunteers. Vox Sanguinis, 103, 213-222.
41. Zipursky, A.L. & Israels, I.G. (1967) The pathogenesis and prevention of Rh immunisation. Canadian Medical Association Journal, 97, 1245-1257.